Athanasia Chatzianastasiou, Sofia-Iris Bibli, Ioanna Andreadou, Panagiotis Efentakis, Nina Kaludercic, Mark E Wood, Matthew Whiteman, Fabio Di Lisa, Andreas Daiber, Vangelis G Manolopoulos, Csaba Szabó, Andreas Papapetropoulos
Journal of Pharmacology and Experimental Therapeutics 2016 Sep;358(3):431-40
DOI: 10.1124/jpet.116.235119View article 🡇
Funding
This work was cofinanced by the European Union (European Social Fund – ESF) and Greek national funds through the Operational Program “Education and Lifelong Learning” of the National Strategic Reference Framework (NSRF) Research Funding Program: Aristeia 2011 (1436) (to A.P.), funds from the Medical Research Council UK (to M.W. and M.E.W.), grants from the Hellenic Institute for the Study of Sepsis (to A.P.) and from the COST Actions BM1005 (ENOG) and BM1203 (EUROS). M.W., M.E.W., and the University of Exeter have intellectual property (patent filings) related to AP39, related compounds and their use.
Keywords: Hydrogen Sulfide